All lobbying filings

THE WASHINGTON TAX & PUBLIC POLICY GROUP

Lobbying for ALLIANCE FOR BIOPHARMACEUTICAL COMPETITIVENESS AND INNOVATION · Biopharmaceutical industry

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · District of Columbia · House · Senate · $450,000.00 income · posted Apr 8, 2025

Official filing document

Bills named in this filing 6

HR 1990
American Innovation and R&D Competitiveness Act of 2025
HR 574
ALIGN Act
HR 1062
Growing and Preserving Innovation in America Act of 2025
S 187
ALIGN Act
HR 1347
AIMM Act
S 559
AIMM Act

Lobbying activity 1

Taxation/Internal Revenue Code

Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income and the potential impacts on the tax base of the U.S. and its Territories. Issues related to IRC sections 11, 164(a), 951A, 250, 163(j), 168, 174 and 41. (H.R.1990, H.R. 574, H.R. 1062, S. 187). Issues related to interest deductibility. (H.R. 1347, S. 559)

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.